Roche lamifiban/heparin arm shows 30% decrease in death/MI at six months; no effect seen at 30-day endpoint.
ROCHE LAMIFIBAN PLUS HEPARIN REDUCES DEATH/MI INCIDENCE 30% AT SIX MONTHS, F. Van de Werf, University Hospital (Leuven, Belgium), said during a symposium on glycoprotein IIb/IIIa receptor antagonists in unstable angina at the European Society of Cardiology meeting in Stockholm Aug. 25. A combination of 300 mcg lamifiban with heparin produced a "statistically significant 30% reduction" of death or myocardial infarction in unstable angina patients, Van de Werf stated.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth